Jennifer Jarrett - 16 Dec 2025 Form 4 Insider Report for Arcus Biosciences, Inc. (RCUS)

Role
Chief Operating Officer
Signature
/s/ Carolyn Tang, Attorney-in-Fact
Issuer symbol
RCUS
Transactions as of
16 Dec 2025
Net transactions value
-$466,870
Form type
4
Filing time
18 Dec 2025, 17:35:14 UTC
Previous filing
12 Nov 2025
Next filing
26 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Jarrett Jennifer Chief Operating Officer C/O ARCUS BIOSCIENCES, INC., 3928 POINT EDEN WAY, HAYWARD /s/ Carolyn Tang, Attorney-in-Fact 18 Dec 2025 0001671311

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCUS Common Stock Sale $245,651 -11,225 -5.2% $21.88 203,007 16 Dec 2025 Direct F1, F2, F3
transaction RCUS Common Stock Sale $221,218 -9,983 -4.9% $22.16 193,024 17 Dec 2025 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents shares sold by the issuer on the reporting person's behalf to cover tax withholding obligations in connection with the vesting of certain RSUs (previously reported in Table I) following the date of grant. The sale occurred automatically pursuant to the Issuer's equity administration policy, which was implemented on May 22, 2025, and does not represent a discretionary trade by the reporting person.
F2 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.42 to $22.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 Includes the unvested portion of the reporting person's RSU grants.
F4 The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.